Sino Biopharmaceutical Limited
SBMFF
$0.9891
$0.03914.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 8.12% | 17.93% | 12.37% | 6.08% | 0.04% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 8.12% | 17.93% | 12.37% | 6.08% | 0.04% |
| Cost of Revenue | 97.53% | 54.72% | -29.42% | -35.79% | -41.39% |
| Gross Profit | 93.79% | 18.39% | -36.96% | -41.16% | -45.01% |
| SG&A Expenses | 87.92% | 17.64% | -36.57% | -41.62% | -46.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 146.81% | 27.30% | -42.23% | -43.54% | -44.71% |
| Total Operating Expenses | 12.04% | 20.28% | 12.15% | 5.91% | -0.06% |
| Operating Income | -6.86% | 9.14% | 13.22% | 6.72% | 0.42% |
| Income Before Tax | 66.18% | 29.00% | -17.37% | -30.21% | -40.82% |
| Income Tax Expenses | -5.07% | 7.21% | 2.03% | -14.13% | -27.93% |
| Earnings from Continuing Operations | 80.06% | 32.84% | -20.47% | -32.73% | -42.82% |
| Earnings from Discontinued Operations | 958.78% | 967.72% | 976.71% | 1,066.25% | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -91.36% | -9.64% | 39.28% | 39.99% | 40.54% |
| Net Income | 47.09% | 82.99% | 127.70% | 47.22% | -9.25% |
| EBIT | -6.86% | 9.14% | 13.22% | 6.72% | 0.42% |
| EBITDA | 19.44% | -16.76% | -15.24% | -17.68% | -20.04% |
| EPS Basic | 48.31% | 84.52% | 129.10% | 47.56% | -8.72% |
| Normalized Basic EPS | 144.12% | 423.08% | 173.68% | -12.24% | -58.02% |
| EPS Diluted | 48.31% | 86.93% | 136.15% | 59.21% | 1.71% |
| Normalized Diluted EPS | 144.12% | 423.08% | 173.68% | -10.42% | -56.96% |
| Average Basic Shares Outstanding | 31.47% | 31.97% | -25.51% | -25.40% | -25.28% |
| Average Diluted Shares Outstanding | -1.31% | -1.35% | -1.48% | -2.00% | -2.52% |
| Dividend Per Share | 38.46% | 3.75% | -22.45% | -43.55% | -56.67% |
| Payout Ratio | -- | -- | -- | -- | -- |